Healthcare innovation is thriving.
Cutting-edge drug discovery technologies are becoming accessible to research labs of all sizes, enabling groundbreaking new insights at a rapid pace.
However, much of the earliest-stage innovation is happening largely out of sight of today’s most active healthcare venture capital firms, which tend to focus on well-established entrepreneurs who have prior wins under their belt. Without essential seed funding, promising early-stage ideas often fail to achieve proof-of-concept, never advancing beyond the lab.
ShangPharma Innovation is a healthcare investment firm that specializes in identifying early-stage gems that can advance quickly with the right combination of funding, scientific expertise and operational support. Our management team and executives-in-residence find and de-risk the brilliant, budding ideas that can become transformative medicines and generate significant investment returns.
“The valley of death is moving earlier and earlier in the drug discovery and development cycle — and as a result, promising therapeutic innovations are dying on the vine.”
— Walter H. Moos, Ph.D., CEO, ShangPharma Innovation